BR112014028222A2 - conjugados vinculadores auto-estabilizantes. - Google Patents
conjugados vinculadores auto-estabilizantes.Info
- Publication number
- BR112014028222A2 BR112014028222A2 BR112014028222A BR112014028222A BR112014028222A2 BR 112014028222 A2 BR112014028222 A2 BR 112014028222A2 BR 112014028222 A BR112014028222 A BR 112014028222A BR 112014028222 A BR112014028222 A BR 112014028222A BR 112014028222 A2 BR112014028222 A2 BR 112014028222A2
- Authority
- BR
- Brazil
- Prior art keywords
- self
- binding conjugates
- stabilizing binding
- stabilizing
- conjugates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261647373P | 2012-05-15 | 2012-05-15 | |
US201361770983P | 2013-02-28 | 2013-02-28 | |
US201361773067P | 2013-03-05 | 2013-03-05 | |
US13/799,244 US9504756B2 (en) | 2012-05-15 | 2013-03-13 | Self-stabilizing linker conjugates |
PCT/US2013/040951 WO2013173337A2 (en) | 2012-05-15 | 2013-05-14 | Self-stabilizing linker conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014028222A2 true BR112014028222A2 (pt) | 2017-06-27 |
Family
ID=49584442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014028222A BR112014028222A2 (pt) | 2012-05-15 | 2013-05-14 | conjugados vinculadores auto-estabilizantes. |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP2850094B1 (pt) |
JP (5) | JP6423340B2 (pt) |
KR (5) | KR102433686B1 (pt) |
CN (2) | CN108465112B (pt) |
AU (5) | AU2013263002C1 (pt) |
BR (1) | BR112014028222A2 (pt) |
CA (2) | CA2869777C (pt) |
EA (1) | EA037203B1 (pt) |
HK (1) | HK1207388A1 (pt) |
MX (2) | MX368678B (pt) |
NZ (3) | NZ741211A (pt) |
SG (2) | SG10201608904YA (pt) |
WO (1) | WO2013173337A2 (pt) |
ZA (1) | ZA201407369B (pt) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
ES2622578T3 (es) | 2011-06-10 | 2017-07-06 | Mersana Therapeutics, Inc. | Conjugados de proteína-polímero-fármaco |
JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
KR102433686B1 (ko) * | 2012-05-15 | 2022-08-19 | 씨젠 인크. | 자가-안정화 링커 접합체 |
AU2014331714B2 (en) | 2013-10-11 | 2019-05-02 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
CN105813655B (zh) | 2013-10-11 | 2022-03-15 | 阿萨纳生物科技有限责任公司 | 蛋白-聚合物-药物缀合物 |
US11103593B2 (en) | 2013-10-15 | 2021-08-31 | Seagen Inc. | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
CN105813653B (zh) | 2013-12-19 | 2020-06-26 | 西雅图基因公司 | 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物 |
WO2016008112A1 (en) * | 2014-07-16 | 2016-01-21 | Medshine Discovery Inc. | Linkers and application towards adc thereof |
PL3191502T3 (pl) * | 2014-09-11 | 2021-11-08 | Seagen Inc. | Ukierunkowane dostarczanie substancji leczniczych zawierających aminę trzeciorzędową |
JP6863888B2 (ja) * | 2014-10-01 | 2021-04-21 | メディミューン,エルエルシー | ポリペプチドをコンジュゲートさせる方法 |
JP6723509B2 (ja) | 2014-10-24 | 2020-07-15 | 日油株式会社 | 環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体 |
EP3226909A1 (en) * | 2014-12-03 | 2017-10-11 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
JP2018502839A (ja) * | 2014-12-09 | 2018-02-01 | アッヴィ・インコーポレイテッド | Bcl−xL阻害性化合物およびこれを含む抗体薬物コンジュゲート |
CA2970155A1 (en) * | 2014-12-09 | 2016-06-16 | Abbvie Inc. | Bcl-xl inhibitory compounds having low cell permeability and antibody drug conjugates including the same |
EP3662933A1 (en) * | 2015-03-18 | 2020-06-10 | Seattle Genetics, Inc. | Cd48 antibodies and conjugates thereof |
CN106267225B (zh) | 2015-05-29 | 2020-03-06 | 上海新理念生物医药科技有限公司 | 三马来酰亚胺型连接子及其应用 |
CN111533778B (zh) * | 2015-07-28 | 2023-04-25 | 上海皓元生物医药科技有限公司 | 一种抗体偶联药物连接子的工业化生产方法 |
TWI727380B (zh) | 2015-11-30 | 2021-05-11 | 美商輝瑞股份有限公司 | 位點專一性her2抗體藥物共軛體 |
AU2016363013B2 (en) | 2015-12-04 | 2022-03-10 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
AU2017237186A1 (en) | 2016-03-25 | 2018-11-01 | Seagen Inc. | Process for the preparation of PEGylated drug-linkers and intermediates thereof |
US11091498B2 (en) | 2016-04-04 | 2021-08-17 | Rutgers, The State University Of New Jersey | Topoisomerase poisons |
KR20190005924A (ko) * | 2016-05-10 | 2019-01-16 | 브리스톨-마이어스 스큅 컴퍼니 | 향상된 안정성을 갖는 튜부리신 유사체의 항체-약물 접합체 |
AU2017277422A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-EGFR antibody drug conjugates |
CN109562170B (zh) | 2016-06-08 | 2023-01-13 | 艾伯维公司 | 抗cd98抗体及抗体药物偶联物 |
EP4104865A1 (en) | 2016-06-08 | 2022-12-21 | AbbVie Inc. | Anti-egfr antibody drug conjugates |
CA3027103A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
MX2018015280A (es) | 2016-06-08 | 2019-08-12 | Abbvie Inc | Conjugados de anticuerpo y farmaco anti-egfr. |
WO2017214456A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
EP3468599A2 (en) | 2016-06-08 | 2019-04-17 | AbbVie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
WO2017214335A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-b7-h3 antibodies and antibody drug conjugates |
MA45945A (fr) | 2016-08-09 | 2019-06-19 | Seattle Genetics Inc | Conjugués de médicaments avec des lieurs auto-stabilisants, aux propriétés physiochimiques améliorées |
KR102617264B1 (ko) | 2016-10-19 | 2023-12-29 | 인벤라 인코포레이티드 | 항체 구조물 |
JP7244987B2 (ja) | 2016-12-14 | 2023-03-23 | シージェン インコーポレイテッド | 多剤抗体薬物コンジュゲート |
EA201991204A1 (ru) | 2016-12-22 | 2019-12-30 | Университа Дельи Студи Манья Греча Катандзаро | Моноклональное антитело против уникального сиалогликозилированного опухолеассоциированного эпитопа cd43 |
US11730822B2 (en) | 2017-03-24 | 2023-08-22 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
CN107652219B (zh) * | 2017-08-14 | 2021-06-08 | 上海新理念生物医药科技有限公司 | 四马来酰亚胺型连接子及其应用 |
US11389543B2 (en) | 2017-09-08 | 2022-07-19 | Seagen Inc. | Process for the preparation of tubulysins and intermediates thereof |
US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
EP3802580A1 (en) | 2018-06-05 | 2021-04-14 | King's College London | Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system |
TW202015740A (zh) | 2018-06-07 | 2020-05-01 | 美商西雅圖遺傳學公司 | 喜樹鹼結合物 |
US20220233708A1 (en) * | 2019-06-28 | 2022-07-28 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Antibody-drug conjugate, intermediate thereof, preparation method therefor and application thereof |
CN114929284A (zh) | 2019-10-04 | 2022-08-19 | 西根公司 | 喜树碱肽缀合物 |
EP4146280A1 (en) * | 2020-05-08 | 2023-03-15 | Mpeg LA, L.l.c. | Linker compounds |
EP4223741A1 (en) * | 2020-09-29 | 2023-08-09 | Mabwell (Shanghai) Bioscience Co., Ltd. | Preparation method for bis-substituted bridging antibody-drug conjugate |
UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
CA3230737A1 (en) | 2021-09-03 | 2023-03-09 | Toray Industries, Inc. | Pharmaceutical composition for cancer treatment and/or prevention |
WO2023178289A2 (en) | 2022-03-17 | 2023-09-21 | Seagen Inc. | Camptothecin conjugates |
EP4321522A1 (en) | 2022-08-12 | 2024-02-14 | Seagen Inc. | Cytotoxic compounds and conjugates thereof |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2036891B (en) | 1978-12-05 | 1983-05-05 | Windsor Smith C | Change speed gear |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Noble hydrazonic history of anthracycline and methods for their preparation |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5091542A (en) * | 1990-03-09 | 1992-02-25 | Hybritech Incorporated | Tris-maleimido compounds as intermediates in trifunctional antibody synthesis |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
EP0648240A1 (en) * | 1992-07-01 | 1995-04-19 | Akzo Nobel N.V. | Process for the modification of polyphenylene ether resin compositions |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
JP2000503639A (ja) | 1995-12-22 | 2000-03-28 | ブリストル―マイヤーズ スクイブ カンパニー | 分枝ヒドラゾンのリンカー類 |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
US6130237A (en) | 1996-09-12 | 2000-10-10 | Cancer Research Campaign Technology Limited | Condensed N-aclyindoles as antitumor agents |
US5973166A (en) | 1998-03-02 | 1999-10-26 | The Dexter Corporation | Method for the preparation of maleimides |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US20030083263A1 (en) | 2001-04-30 | 2003-05-01 | Svetlana Doronina | Pentapeptide compounds and uses related thereto |
US8877901B2 (en) * | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US7432331B2 (en) * | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
KR101520209B1 (ko) * | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
EP1747021B1 (en) | 2004-05-19 | 2015-09-09 | E. R. Squibb & Sons, L.L.C. | Self-immolative linkers and drug conjugates |
US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
NZ551180A (en) | 2004-06-01 | 2009-10-30 | Genentech Inc | Antibody drug conjugates and methods |
WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
CA2614436C (en) | 2005-07-07 | 2016-05-17 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus |
CN101312748A (zh) | 2005-09-26 | 2008-11-26 | 梅达莱克斯公司 | 抗体-药物轭合物和使用方法 |
SI1813614T1 (sl) | 2006-01-25 | 2012-01-31 | Sanofi 174 | Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate |
HUE031533T2 (hu) | 2007-10-19 | 2017-07-28 | Seattle Genetics Inc | CD19-kötõszerek valamint alkalmazásuk |
NO2842575T3 (pt) | 2008-03-18 | 2018-02-24 | ||
US8236319B2 (en) | 2008-04-30 | 2012-08-07 | Immunogen, Inc. | Cross-linkers and their uses |
RU2011125366A (ru) * | 2008-12-05 | 2013-01-10 | Ангиочем Инк. | Конъюгаты терапевтических пептидов и их применение |
EP3360879A1 (en) | 2009-02-05 | 2018-08-15 | ImmunoGen, Inc. | Benzodiazepine derivatives as cytotoxic agents |
EP3243527B1 (en) * | 2009-02-13 | 2019-06-05 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
KR101738203B1 (ko) | 2010-04-15 | 2017-05-19 | 메디뮨 리미티드 | 피롤로벤조디아제핀 및 그의 컨주게이트 |
JP6121906B2 (ja) * | 2010-10-22 | 2017-04-26 | シアトル ジェネティクス,インコーポレーテッド | アウリスタチン系抗体薬物複合体とPI3K−AKTmTOR経路インヒビターの間の相乗効果 |
MX346635B (es) | 2011-02-15 | 2017-03-27 | Immunogen Inc | Derivados citotoxicos de la benzodiazepina. |
KR102433686B1 (ko) * | 2012-05-15 | 2022-08-19 | 씨젠 인크. | 자가-안정화 링커 접합체 |
EP2968591A1 (en) * | 2013-03-15 | 2016-01-20 | Novartis AG | Cell proliferation inhibitors and conjugates thereof |
-
2013
- 2013-05-14 KR KR1020207022850A patent/KR102433686B1/ko active IP Right Grant
- 2013-05-14 CA CA2869777A patent/CA2869777C/en active Active
- 2013-05-14 KR KR1020227042635A patent/KR102557309B1/ko active IP Right Grant
- 2013-05-14 JP JP2015512756A patent/JP6423340B2/ja active Active
- 2013-05-14 CN CN201810349815.9A patent/CN108465112B/zh active Active
- 2013-05-14 NZ NZ74121113A patent/NZ741211A/en unknown
- 2013-05-14 NZ NZ630870A patent/NZ630870A/en unknown
- 2013-05-14 AU AU2013263002A patent/AU2013263002C1/en active Active
- 2013-05-14 EA EA201401254A patent/EA037203B1/ru unknown
- 2013-05-14 CA CA3131619A patent/CA3131619A1/en not_active Abandoned
- 2013-05-14 BR BR112014028222A patent/BR112014028222A2/pt not_active Application Discontinuation
- 2013-05-14 SG SG10201608904YA patent/SG10201608904YA/en unknown
- 2013-05-14 KR KR1020147034652A patent/KR102144069B1/ko active Application Filing
- 2013-05-14 MX MX2014013807A patent/MX368678B/es active IP Right Grant
- 2013-05-14 KR KR1020237024059A patent/KR20230113821A/ko not_active Application Discontinuation
- 2013-05-14 EP EP13791383.6A patent/EP2850094B1/en active Active
- 2013-05-14 KR KR1020217023061A patent/KR102475777B1/ko active IP Right Grant
- 2013-05-14 CN CN201380025771.XA patent/CN104822656B/zh active Active
- 2013-05-14 SG SG11201406252WA patent/SG11201406252WA/en unknown
- 2013-05-14 NZ NZ724892A patent/NZ724892A/en unknown
- 2013-05-14 WO PCT/US2013/040951 patent/WO2013173337A2/en active Application Filing
-
2014
- 2014-10-10 ZA ZA2014/07369A patent/ZA201407369B/en unknown
- 2014-11-13 MX MX2019012201A patent/MX2019012201A/es unknown
-
2015
- 2015-08-19 HK HK15108030.8A patent/HK1207388A1/xx unknown
-
2018
- 2018-02-19 AU AU2018201190A patent/AU2018201190B2/en active Active
- 2018-05-21 JP JP2018097123A patent/JP6709247B2/ja active Active
-
2020
- 2020-04-28 AU AU2020202805A patent/AU2020202805B2/en active Active
- 2020-05-22 JP JP2020089453A patent/JP7014856B2/ja active Active
-
2021
- 2021-03-16 AU AU2021201636A patent/AU2021201636B2/en active Active
-
2022
- 2022-01-20 JP JP2022007056A patent/JP7431261B2/ja active Active
-
2023
- 2023-05-15 AU AU2023203005A patent/AU2023203005A1/en active Pending
-
2024
- 2024-02-01 JP JP2024014096A patent/JP2024032941A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR23C1020I1 (fr) | Conjugues pyrrolobenzodiazepine-anticorps | |
BR112014028222A2 (pt) | conjugados vinculadores auto-estabilizantes. | |
HRP20181646T1 (hr) | Konjugati pirolobenzodiazepin - anti-psma protutijela | |
ZA201502267B (en) | Pyrrolobenzodiazepine-anti-her2 antibody conjugates | |
ZA201502523B (en) | Pyrrolobenzodiazepine-anitbody conjugates | |
DK2906251T3 (da) | Pyrrolobenzodiazepin-anti-CD22-antistofkonjugater | |
DK2920304T3 (da) | Oligonukleotidkonjugater | |
PL2877490T3 (pl) | Inteiny podzielone, koniugaty i ich zastosowania | |
ZA201408914B (en) | Conjugation reagents | |
EP2917244A4 (en) | ANTIBODY CONJUGATES OBTAINED FROM APROTININE | |
IL233701A0 (en) | Conjugates of a binding molecule | |
FR2986872B1 (fr) | . | |
BR112014027645A2 (pt) | 5-halogenopirazol bifenilcarboxamidas. | |
ES1076713Y (es) | Altillo de estructura abatible. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 207/40 Ipc: C07D 207/40 (2006.01), A61P 35/00 (2006.01), A61K |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B25D | Requested change of name of applicant approved |
Owner name: SEAGEN INC. (US) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |